Risk of logistics disruption and difficulty ensuring a stable supply due to the spread of COVID-19
First written in FY2020. 2 of 4 entries say "Mitigated", first in FY2021-Q1. Latest entry: FY2021.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
- FY2021MitigatedAnnual report
「As a company responsible for the stable supply of life-related products, the Group is preparing for various situations that may arise in connection with the spread of COVID-19. We are working to maintain a stable supply system, including mutual support among logistics centers nationwide, adequate product inventories, temperature checks for visitors entering facilities using thermal cameras, and advancing the scheduled maintenance of equipment, as well as to prevent the spread of infection through thorough infection prevention measures for employees, cleaning and disinfection of vehicles and equipment, and prevention of the spread of infection at medical institutions.」
The Company disclosed specific measures including mutual backup among logistics centers nationwide, increased inventories, thermal cameras, advance maintenance, and disinfection. - FY2021-Q2RestatedAnnual report
「As measures against COVID-19, we are continuing to maintain a stable supply of pharmaceuticals and other products by taking various measures under the guidance of infection-control specialists to ensure the safety of customers and employees, including refraining from in-person sales activities at medical institutions and thoroughly cleaning and disinfecting vehicles and equipment.」
As measures against the risk of logistics functions shutting down and difficulty maintaining a stable supply due to the spread of COVID-19, the Company continued to refrain from in-person sales activities and clean and disinfect vehicles and equipment. - FY2021-Q1MitigatedAnnual report
「Since the declaration of a state of emergency was issued, we have refrained from in-person sales activities at medical institutions to ensure the safety of customers and employees, while continuing to maintain a stable supply of pharmaceuticals and other products by taking various measures under the guidance of infection-control specialists, including thorough cleaning and disinfection of vehicles and equipment.」
In response to the risk of logistics functions shutting down due to the spread of COVID-19, the Company took infection-control measures such as refraining from in-person sales activities and cleaning and disinfecting vehicles and equipment, while continuing to maintain a stable supply. - FY2020First statedAnnual report
「However, if the logistics function were to cease, for example because infections spread among employees of the Group, it could become difficult to maintain a stable supply of pharmaceuticals and other products, potentially affecting the Group's operating performance and financial position.」
Regarding COVID-19, the Company identified the shutdown of logistics functions originating from the spread of infection among employees and the resulting difficulty in maintaining a stable supply of pharmaceuticals and other products as new business and other risks.